Get the Stockscreener App
106.66
1.89%
-2.05
Pre-market:
106.90
0.24
+0.23%
Illumina Inc stock is traded at $106.66, with a volume of 1.71M.
It is down -1.89% in the last 24 hours and up +12.52% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$108.71
Open:
$109.07
24h Volume:
1.71M
Relative Volume:
0.78
Market Cap:
$16.88B
Revenue:
$4.34B
Net Income/Loss:
$-965.00M
P/E Ratio:
-17.57
EPS:
-6.07
Net Cash Flow:
$869.00M
1W Performance:
+1.96%
1M Performance:
+12.52%
6M Performance:
-19.81%
1Y Performance:
-12.93%
1-Day Range:
$105.69
$109.59
1-Week Range:
$104.53
$111.00
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
106.66 | 17.21B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
477.28 | 182.01B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.99 | 148.12B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
572.09 | 46.09B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
118.05 | 34.04B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.54 | 33.07B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics - sharewise.com
Illumina Releases TSO 500 v2 Assay with Integrated HRD Detection and Reduced Sample Requirements - geneonline.com
Illumina To Pay $9.8M To Resolve Cybersecurity Qui Tam Case - Law360
Veterinary scientists from 39 states gather to learn whole-genome sequencing - Illumina
Illumina enhances flagship cancer research assay with new features - Investing.com Australia
Illumina enhances flagship cancer research assay with new features By Investing.com - Investing.com South Africa
Illumina's New Cancer Test Breakthrough: Built-in HRD Detection Makes Tumor Profiling Faster and Easier - Stock Titan
Global Cancer Profiling Market Outlook to 2031: Growth Insights with Illumina, Qiagen, Thermo Fisher, and Roche - openPR.com
Illumina (ILMN) To Report Earnings Tomorrow: Here Is What To Expect - FinancialContent
DNA Sequencing Market Exclusive Report with Detailed Study - openPR.com
INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
What are Illumina Inc. company’s key revenue driversSmart Portfolio Recommendation For Beginners - jammulinksnews.com
Does Illumina Inc. stock perform well during market downturnsSwing Trade Outlook For Every Investor - jammulinksnews.com
Illumina (ILMN) Stock Is Up, What You Need To Know - Yahoo Finance
What is Illumina Inc. company’s growth strategyBreakout stock performance - jammulinksnews.com
How strong is Illumina Inc. company’s balance sheetTurbocharged investment results - jammulinksnews.com
What institutional investors are buying Illumina Inc. stockBuild wealth steadily with proven investment strategies - jammulinksnews.com
How many analysts rate Illumina Inc. as a “Buy”Free Predictions - jammulinksnews.com
What drives Illumina Inc. stock priceOutstanding stock performance - PrintWeekIndia
Illumina Inc. Stock Analysis and ForecastSky-high profits - PrintWeekIndia
U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth - GlobeNewswire Inc.
Does Illumina Inc. stock pay reliable dividendsOutperformance with explosive growth - jammulinksnews.com
Is Illumina Inc. a good long term investmentStrongest growth potential - PrintWeekIndia
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Microfluidic Market To Witness Substantial Growth, 2025-2032 | - openPR.com
(ILMN) Investment Analysis and Advice - news.stocktradersdaily.com
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
ILLUMINA, INC. (ILMN) - MSN
Whole Genome Sequencing Market Booming, to Reach US$ 8,608 - openPR.com
Multi-Omics Market Attracts Big Players, to Hit $33.25B by 2033 | - openPR.com
What analysts say about Illumina Inc. stockOutstanding growth strategies - Autocar Professional
Lobbying Update: $410,000 of ILLUMINA INC. lobbying was just disclosed - Quiver Quantitative
DNA Test Kits Market Booming with Consumer Genomics Demand - openPR.com
Bioinformatics Services Market Surge Backed by Genomics - openPR.com
Illumina India Wins the Top GCC Award at the 2025 GCC Workplace Awards - Tribune India
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):